Understanding how IDH-mutant gliomas respond to specific cancer treatments
Official title: Dissecting the Determinants of IDH-mutant Gliomas Response to Mutant IDH Inhibitors
Funded at Massachusetts General Hospital · NIH-10931469 · Data updated 2026-11-12
This study is looking at how different brain tumors called IDH-mutant gliomas react to new treatments that target their specific mutations, with the goal of figuring out why some tumors get better while others don’t, so we can create more tailored treatment plans for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $652,794 |
| NIH project number | 5R01CA276765-02 |
| Project ID | NIH-10931469 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with IDH-mutant gliomas, particularly those who may be considering treatment with mutant IDH inhibitors.
✕Less likely to help
Patients with gliomas that do not have IDH mutations or those who are not eligible for treatment with mutant IDH inhibitors may not benefit from this research.
What this research studies
This research investigates the responses of IDH-mutant gliomas, a type of brain cancer, to mutant IDH inhibitors, which are potential treatments. The study aims to identify why some tumors respond positively to these inhibitors while others do not, using advanced techniques like single-cell multi-omics analysis. By examining tumor samples from patients, the research seeks to uncover the intrinsic and extrinsic factors that influence treatment outcomes. This could lead to more personalized treatment strategies for patients with this type of cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with IDH-mutant gliomas.
How similar studies have gone: Previous research has shown mixed results with similar approaches, indicating that while some patients may benefit from IDH inhibitors, the responses can vary significantly.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Suva, Mario Luca — Massachusetts General Hospital
- Study coordinator: Suva, Mario Luca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.